
07/16/2025
We are proud to announce that the Department of Psychiatry at Massachusetts General Hospital (MGH) has established the Joseph Biederman, MD Psychiatry Grand Rounds lecture in pediatric psychopharmacology. This endowed lecture honors the memory of Dr. Biederman, the founder of the Alan and Lorraine Bressler Program Clinical and Research Program for Autism Spectrum Disorder. Dr. Biederman’s groundbreaking research in the field of psychiatry spanned multiple areas, including autism, ADHD, emotional dysregulation, mood disorders and anxiety disorders. He created the field of pediatric psychopharmacology which ushered in a new paradigm for treating childhood psychiatric illness. As one of the world’s most influential psychiatrists, Dr. Biederman’s body of work spanned 40 years helping countless individuals and training generations of child psychiatrists. The Joseph Biederman, MD Grand Rounds lecture ensures that his legacy of teaching and research continues.
This spring, the lecture was delivered by Gagan Joshi, MD, the Director of the Bressler Program for Autism Spectrum Disorder at MGH. Dr. Joshi presented his research on the psychopathology, prevalence, assessment, treatment, and psychiatric comorbidities associated with autism. With mentorship and collaboration from Dr. Biederman, Dr. Joshi recognized the importance of creating this clinic in response to the rising prevalence and under-recognition of autism in intellectually capable populations. His research examined the clinical correlates of ASD in psychiatrically referred populations and discussed screening and assessment approaches designed to improve identification in these settings. Dr. Joshi highlighted that over two-thirds of youth with ASD experience co-occurring psychopathology, including ADHD, anxiety, mania, and mood disorders. Recognizing these psychiatric conditions is essential for frequently diagnosing co-occurring psychiatric disorders and providing disorder-specific, targeted treatment. While there are currently no recognized treatments for the management of social deficits in ASD, Dr. Joshi’s presentation demonstrated how neuroimaging-informed pharmacotherapy can be leveraged for treatment of a subtype of autism. His research examined glutamate dysregulation in autism and how altered brain glutamate activity may serve as a biomarker for treatment response. In Dr. Joshi’s Namenda study, he found that patients with elevated glutamate responded well to memantine, a glutamate modulator, showing both symptom relief and high tolerability. Thank you, Dr. Joshi, for sharing your research with us during your moving and innovative lecture.